Systems Oncology Approach to Optimize Ovarian Cancer Treatment

Recruiting

• Conditions: Ovarian Cancer

• Registration Number: NCT06117384
• Lead Sponsor: University of Helsinki

Brief Summary

The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-01
• Study First Submitted: 2023-10-21
• Status Verified: 2023-11
• Study First Submitted QC: 2023-11-01
• Last Update Submitted: 2023-11-01
• Study First Posted: 2023-11-07
• Last Update Posted: 2023-11-07
• Primary Completion: 2027-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

• Patients diagnosed with ovarian cancer
• Available tumor tissue/blood samples

Exclusion Criteria

• Inability to consent to the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recruitment and collection of real-world clinical data from ovarian cancer patients	5 years	Prospective recruitment and collection of clinical data from 500 ovarian cancer patients. Fraction of patients from which the collection of clinical data including patient age, tumor stage, histological diagnoses have been collected.
Successful collection and translational analysis of biospecimens	5 years	Fraction of the recruited patients, from which tumor, ascites, and/or peripheral blood samples that have been successfully collected and subjected to molecular profiling.

Secondary Outcome Measures

Name	Time	Method
Discovery of candidate prognostic and predictive biomarkers	5 years	Number of clinical and/or molecular features which of statistically significantly correlate to patient treatment outcomes (response to chemotherapy by RECIST1.1, Progression Free survival, Overall Survival).

Trial Locations

Locations (1)

Helsinki University and Helsinki University Hospital; 🇫🇮 Helsinki, Finland